Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
Headache: The Journal of Head and Face Pain · 2023-01 · 63 (1) · 79-88
DOI: 10.1111/head.14439 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 18.01.2023. Verfasst von Messoud Ashina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen…. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Objective
To assess long‐term safety, tolerability, and efficacy of once‐daily oral atogepant 60 mg in adults with migraine.
Background
Atogepant is an oral, small‐molecule, calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of episodic migraine.
Methods
A 52‐week, multicenter, randomized, open‐label trial of adults (18–80 years) with migraine. Lead‐in trial completers or newly enrolled participants with 4–14 migraine days/month were enrolled and randomized (5:2) to atogepant 60 mg once daily or oral standard care (SC) migraine preventive medication. The primary objective was to evaluate the safety and tolerability of atogepant; safety assessments included treatment‐emergent adverse events (TEAEs), clinical laboratory evaluations, vital signs, and Columbia‐Suicide Severity Rating Scale scores. Efficacy assessments (atogepant only) included change from baseline in mean monthly migraine days (MMDs) and the proportion of participants with reductions from baseline of ≥50%, ≥75%, and 100% in MMDs.
Results
The trial included 744 participants randomized to atogepant 60 mg ( n = 546) or SC ( n = 198). The atogepant safety population was 88.2% female ( n = 479/543) with a mean (standard deviation) age of 42.5 (12.0) years. TEAEs occurred in 67.0% ( n = 364/543) of participants treated with atogepant 60 mg. The most commonly reported TEAEs (≥5%) were upper respiratory tract infection (10.3%; 56/543), constipation (7.2%; 39/543), nausea (6.3%; 34/543), and urinary tract infection (5.2%; 28/543). Serious TEAEs were reported in 4.4% (24/543) for atogepant. Mean (standard error) change in MMDs for atogepant was −3.8 (0.1) for weeks 1–4 and −5.2 (0.2) at weeks 49–52. Similarly, the proportion of participants with ≥50%, ≥75%, and 100% reductions in MMDs increased from 60.4% (310/513), 37.2% (191/513), and 20.7% (106/513) at weeks 1–4 to 84.2% (282/335), 69.9% (234/335), and 48.4% (162/335), at weeks 49–52.
Conclusion
Daily use of oral atogepant 60 mg for preventive treatment of migraine during this 1‐year, open‐label trial was safe, well tolerated, and efficacious.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
- Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Headache Center of Southern California, Carlsbad, California, USA.
- Orange County Migraine and Headache Center, Irvine, California, USA.
- AbbVie, Madison, New Jersey, USA.
ORCID-Profile: Messoud Ashina, Susan Hutchinson
Förderung
- AbbVie
Zitieren
APA
Ashina, M., Tepper, S. J., Reuter, U., Blumenfeld, A. M., Hutchinson, S., Xia, J., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2023). Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache: The Journal of Head and Face Pain, 63(1), 79-88. https://doi.org/10.1111/head.14439
Vancouver
Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, et al. Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache: The Journal of Head and Face Pain. 2023;63(1):79-88. doi:10.1111/head.14439
BibTeX
@article{Ashina2023,
author = {Ashina, Messoud and Tepper, Stewart J and Reuter, Uwe and Blumenfeld, Andrew M and Hutchinson, Susan and Xia, Jing and Miceli, Rosa and Severt, Lawrence and Finnegan, Michelle and Trugman, Joel M},
title = {Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial},
journal = {Headache: The Journal of Head and Face Pain},
year = {2023},
volume = {63},
number = {1},
pages = {79--88},
doi = {10.1111/head.14439}
}
EUVIMED